HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riches, F. M. Articles by Talmud, P. J. Search for Related Content PubMed PubMed Citation Articles by Riches, F. M. Articles by Talmud, P. J. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 39, 1752-1758, September 1998
Copyright © 1998 by Lipid Research, Inc.

Original Article

Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men

Correspondence to: G. F. Watts.

We aimed to examine the effect of genetic polymorphisms of apolipoprotein B-100 (apoB) signal peptide and apolipoprotein E (apoE) on the hepatic secretion of very low density lipoprotein (VLDL) apoB in 29 men with visceral obesity. We studied apoB secretion using a primed (1 mg/kg), constant (1 mg/kg/h) intravenous infusion of [1-¹³C]leucine. The isotopic enrichment of VLDL apoB was determined using gas chromatography–mass spectrometry (GCMS). A multi-compartmental model was used to estimate the fractional turnover rate of VLDL apoB. Genotypes for the apoB signal peptide length polymorphism, 27 amino acid (SP27) and 24 amino acid (SP24), and apoE genotypes were determined using polymerase chain reaction. In subjects who were not apoE2 carriers and were homozygous for the SP27 of the apoB signal peptide, the hepatic secretion of VLDL apoB was significantly higher than in subjects who were not apoE2 carriers and were either heterozygous or homozygous for the SP24 allele (31.3 ± 11.8 mg/kg fat-free mass/day, n = 8 vs. 16.9 ± 12.2 mg/kg fat-free mass/day, n = 13, P = 0.01). In subjects who were not apoE4 carriers and were either heterozygous or homozygous for the apoB SP24 allele, the hepatic secretion of VLDL apoB was significantly lower than in subjects who were not apoE4 carriers and were homozygous for the SP27 allele (15.8 ± 12.9 mg/kg fat-free mass/day, n = 13 vs. 27.4 ± 11.5 mg/kg fat-free mass/day, n = 7, P = 0.03).

The data suggest that in men with visceral obesity, the apoB signal peptide and apoE genotypes appear to be involved in the hepatic secretion of apoB.—Riches, F. M., G. F. Watts, F. M. van Bockxmeer, J. Hua, S. Song, S. E. Humphries, and P. J. Talmud. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. J. Lipid Res. 1998. 39: 1752–1758.

Supplementary key words: very low density lipoprotein, apoB-100, genotype, visceral obesity, stable isotope

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753. [Abstract] [Full Text] [PDF]

				D.C. Chan, G.F. Watts, P.H.R. Barrett, A.J. Whitfield, and F.M. van Bockxmeer ATP-Binding Cassette Transporter G8 Gene As a Determinant of Apolipoprotein B-100 Kinetics in Overweight Men Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2188 - 2191. [Abstract] [Full Text] [PDF]

				D. C. Chan, G. F. Watts, P. H. R. Barrett, T. A. Mori, L. J. Beilin, and T. G. Redgrave Mechanism of Action of a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor on Apolipoprotein B-100 Kinetics in Visceral Obesity J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2283 - 2289. [Abstract] [Full Text] [PDF]

				R. Batal, M. Tremblay, P. H. R. Barrett, H. Jacques, A. Fredenrich, O. Mamer, J. Davignon, and J. S. Cohn Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects J. Lipid Res., May 1, 2000; 41(5): 706 - 718. [Abstract] [Full Text]

				G. F. Watts, F. M. Riches, S. E. Humphries, P. J. Talmud, and F. M. van Bockxmeer Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity J. Lipid Res., March 1, 2000; 41(3): 481 - 488. [Abstract] [Full Text]

				E. R. Christ, P. V. Carroll, E. Albany, A. M. Umpleby, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, and D. L. Russell-Jones Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1154 - E1162. [Abstract] [Full Text] [PDF]